Roundtable Discussion; The Future of Mineral Sands. Watch the video here.
BH, have a look at third pic : https://twitter.com/Larry64450205/status/1565251934122115072?t=RcKECqvlb6VE6VNz78mehQ&s=19
The defendents (ncyt) are represented by Andrew Twigger etc
Hi Poidster, totaly agree as very often.
"So the test supplied was FIT FOR PURPOSE and approved by the NHS." ... And plenty of others : ctda, private labs, several NHSs, etc.
Fyi, fwiw, one Can find warranty on page 17 :
https://atamis-1928.cloudforce.com/sfc/p/#0O000000rwim/a/4J000000kEFW/0a.XEpAnsXhWLPDFwBk_JAjjG7TOqEVnG58sfxOiFmw
In this part : "Supplier’s maximum liability with any Authority claim under this warranty shall be to replace the faulty Goods free of charge or refund to the Authority the full costs for such faulty Goods paid by the Authority to the Supplier if replacement is not possible. "
IF they were deemed faulty, what i dont think, replacement IS possible with PROmate. They even bought for several millions of it... So yeah wtf is dhsc playing at...
"Strong contractual rights" BoD told us.
Re sales of goods act, havent found the courage to go into it lol
@poidster, whats your @ on twitter ?
Secretary of State for Health and Social Care v. Primer Design Ltd – Andrew is instructed in relation to a multi-million pound dispute in the Technology and Construction Court arising out of an agreement to supply Rapid-PCR test kits in the last quarter of 2020. The dispute concerns the meaning and effect of a “limited warranty” in the agreement and whether the rejection of certain of the test kits was valid. There are also issues turning on the meaning and effect of provisions in the Sale of Goods Act 1979.
https://www.maitlandchambers.com/our-people/barristers/kings-counsel/andrew-twigger
@Poidster, hi, i cant Say a dissagree with what you say ! Im thinking the same for most of it.
Theznegativity of rns, the secrety, as you say, been shamefull.
But i think, i Hope, that some news are coming.
New CE-IVD assays should be launched soon. Versalab expanding, e-commerce, and FY results in the week of 24 April with outlook.
A Big concern is, will it be good, will it be positive, will it be clear and without hiding half of what they're doing, etc. And will it be just one rns before 6/12 months of more silence ? W&S.
One thing they told us last year though, those New multiplex will take 12 to 18/24 months. We are at 12. So news are expected. In the meantime, i also kind of understand there might not be much to Say.
Of course earth has stopped turning with DA leaving.
The 200 ppl hired are waiting for a New ceo while doing nothing, the other BoD members are doing nothing too, at best looking for a New CEO.
BoD had agreed with that strategy, even if something made them thank DA later.
The development of such multiplex i quoted above is a good strategy.
And in the meantime, until theyre all ready and launched, selling others assays is also good.
Versalab is starting to expand into diagnostic diseases in general.
Even the American Society for microbiology tells multiplex are important. and thats what ncyt seems to be developping.
https://asm.org/Press-Releases/2023/March/PCR-Panels-Reduce-Costs,-Hospitalizations-and-Anti
Nothing in the pipeline at all... Yeaaaah yeah...
"the Company will initially focus on the following therapeutic areas for organic R&D investment:
· Seasonal respiratory diseases, where the testing market is estimated to be worth approximately $1.4bn and is growing at a CAGR of approximately 4%. Through its research, Novacyt has confirmed it is already on the right track with its ongoing development of a respiratory panel for COVID-19 combining influenza A/B and RSV A/B (WinterpanelTM). The Company is also evaluating the need for additional respiratory panels, including atypical pneumonia to cover bacteria, such as bordetella, legionella and mycoplasma, and panels for other respiratory viruses such as parainfluenza, adenovirus and rhinovirus.
· Gastro-intestinal (GI) infections and is embarking on the development of viral panels covering viruses such as norovirus, rotavirus and adenovirus and a bacterial panel to include bacteria such as clostridium difficile, salmonella, shigella. These panels will be designed for a near-patient workflow that can be deployed in "spoke labs" such as in medium district general hospitals, community hospitals, hospital wards or for example in nursing homes, amongst other possible settings. The global GI testing market is estimated to be worth over $630m and is growing at a CAGR of approximately 5%.
· The Company had, prior to undertaking its market research, embarked on developing single analyte transplant products for cytomegalovirus, Epstein-Barr virus and BK virus infections on its genesig® platform, which can be run on existing laboratory systems, with extraction, where sample flexibility and sensitivity are key, and quantification of viral load is required. The Company continues to see this as a growth opportunity, with the global transplant market for monitoring viral load in immunocompromised patients estimated to be worth $151m with a CAGR of approximately 5%.
· Novacyt is embarking on the development of a viral panel for insect borne diseases, such as Dengue, Zika and Yellow fever, where the Company already has RUO assays. As mosquitos' habitats expand, rates of these associated diseases are increasing and have become a priority for the WHO, which has led to the launch of the organisation's Global Arbovirus Initiative. Including this panel in the development strategy not only expands its test menu and serves unmet needs, in combination with its near patient workflow, but also aligns squarely with the Company's "global first responder" strategy of tackling outbreaks and supporting neglected tropical disease diagnosis. The global market for insect borne viral diseases is estimated to be worth $156m, growing at a CAGR of approximately 5%."
And mygos in labs...
https://twitter.com/Larry64450205/status/1637704908882206720?t=m68skks9U9A2CfpCkicWQg&s=19
https://twitter.com/Larry64450205/status/1636961115954376706?t=YRdFOxIR8MwfMpfXEp9Lmw&s=19
https://twitter.com/Larry64450205/status/1636699614312034310?t=lkcG8E2VB36s7khrOCFTSg&s=19
https://twitter.com/Larry64450205/status/1636436111189786638?t=UpvPdE0N3XI2NbdjK704lw&s=19
https://twitter.com/Larry64450205/status/1636443717891489793?t=xkbsj8SOQRO9zTB24syz0w&s=19
A very versatile instrument...
https://protondx.com/news/protondx-welcomes-new-cfo-ann-wong-to-drive-scale-up-and-commercial-expansion/
News for protonDx today btw.
Shooting continues at RD labs at ncyt in Southampton today and tomorrow.
Katalyst showed a pic of the shooting last week at their lab in Soho. "Shooting a short film with our partner novacyt" Katalyst wrote.
Dunno about protonDx, but imho, Katalyst and Versalab/ncyt will continue.
https://twitter.com/Larry64450205/status/1633897188244766736?t=lemSfAzjNnVzpc9F9KSUSw&s=19
Already seen ;)